229 related articles for article (PubMed ID: 15908653)
1. Neoadjuvant immunotherapy of oral squamous cell carcinoma modulates intratumoral CD4/CD8 ratio and tumor microenvironment: a multicenter phase II clinical trial.
Tímár J; Ladányi A; Forster-Horváth C; Lukits J; Döme B; Remenár E; Godény M; Kásler M; Bencsik B; Répássy G; Szabó G; Velich N; Suba Z; Elo J; Balatoni Z; Pócza K; Zemplén B; Chretien P; Talor E
J Clin Oncol; 2005 May; 23(15):3421-32. PubMed ID: 15908653
[TBL] [Abstract][Full Text] [Related]
2. The effect of leukocyte interleukin injection (Multikine) treatment on the peritumoral and intratumoral subpopulation of mononuclear cells and on tumor epithelia: a possible new approach to augmenting sensitivity to radiation therapy and chemotherapy in oral cancer--a multicenter phase I/II clinical Trial.
Tímár J; Forster-Horváth C; Lukits J; Döme B; Ladányi A; Remenár E; Kásler M; Bencsik M; Répássy G; Szabó G; Velich N; Suba Z; Elõ J; Balatoni Z; Bajtai A; Chretien P; Talor E
Laryngoscope; 2003 Dec; 113(12):2206-17. PubMed ID: 14660929
[TBL] [Abstract][Full Text] [Related]
3. [The effect of the microenvironment of head and neck cancers on tumor progression].
Lukits J
Magy Onkol; 2009 Mar; 53(1):51-9. PubMed ID: 19318327
[TBL] [Abstract][Full Text] [Related]
4. Phase-II randomized study of preoperative IL-2 administration in radically operable gastric cancer patients.
Romano F; Piacentini MG; Franciosi C; Caprotti R; De Fina S; Cesana G; Uggeri F; Conti M; Uggeri F
Hepatogastroenterology; 2004; 51(60):1872-6. PubMed ID: 15532847
[TBL] [Abstract][Full Text] [Related]
5. The number of intratumoral dendritic cells and zeta-chain expression in T cells as prognostic and survival biomarkers in patients with oral carcinoma.
Reichert TE; Scheuer C; Day R; Wagner W; Whiteside TL
Cancer; 2001 Jun; 91(11):2136-47. PubMed ID: 11391595
[TBL] [Abstract][Full Text] [Related]
6. Tumor-infiltrating lymphocytes, particularly the balance between CD8(+) T cells and CCR4(+) regulatory T cells, affect the survival of patients with oral squamous cell carcinoma.
Watanabe Y; Katou F; Ohtani H; Nakayama T; Yoshie O; Hashimoto K
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 May; 109(5):744-52. PubMed ID: 20303300
[TBL] [Abstract][Full Text] [Related]
7. Clinical experience with HLA-B7 plasmid DNA/lipid complex in advanced squamous cell carcinoma of the head and neck.
Gleich LL; Gluckman JL; Nemunaitis J; Suen JY; Hanna E; Wolf GT; Coltrera MD; Villaret DB; Wagman L; Castro D; Gapany M; Carroll W; Gillespie D; Selk LM
Arch Otolaryngol Head Neck Surg; 2001 Jul; 127(7):775-9. PubMed ID: 11448348
[TBL] [Abstract][Full Text] [Related]
8. [Effect of local immunotherapy of interleukin 2(IL-2) in combination with chemotherapy upon intratumoral lymphocytes in oral squamous cell carcinomas].
Tang E; Hu Q; Zhou B
Hua Xi Kou Qiang Yi Xue Za Zhi; 2003 Dec; 21(6):444-6. PubMed ID: 14732977
[TBL] [Abstract][Full Text] [Related]
9. Biological, histological, and clinical impact of preoperative IL-2 administration in radically operable gastric cancer patients.
Romano F; Cesana G; Berselli M; Gaia Piacentini M; Caprotti R; Bovo G; Uggeri F
J Surg Oncol; 2004 Dec; 88(4):240-7. PubMed ID: 15565596
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of a novel oral formation of 5-fluorouracil in combination with low-dose cisplatin as preoperative chemotherapy of oral squamous cell carcinoma.
Nakazawa M; Ohnishi T; Ohmae M; Chisoku H; Yui S; Iwai S; Sumi T; Fukuda Y; Kishino M; Yura Y
Int J Clin Pharmacol Res; 2005; 25(3):115-22. PubMed ID: 16366419
[TBL] [Abstract][Full Text] [Related]
11. A trial of IRX-2 in patients with squamous cell carcinomas of the head and neck.
Hadden J; Verastegui E; Barrera JL; Kurman M; Meneses A; Zinser JW; de la Garza J; Hadden E
Int Immunopharmacol; 2003 Aug; 3(8):1073-81. PubMed ID: 12860164
[TBL] [Abstract][Full Text] [Related]
12. Differential regulation of IL-2 and IL-4 in patients with tobacco-related oral squamous cell carcinoma.
Manchanda P; Sharma SC; Das SN
Oral Dis; 2006 Sep; 12(5):455-62. PubMed ID: 16910915
[TBL] [Abstract][Full Text] [Related]
13. Fas ligand expression in metastatic renal cell carcinoma during interleukin-2 based immunotherapy: no in vivo effect of Fas ligand tumor counterattack.
Donskov F; von der Maase H; Marcussen N; Hamilton-Dutoit S; Madsen HH; Jensen JJ; Hokland M
Clin Cancer Res; 2004 Dec; 10(23):7911-6. PubMed ID: 15585624
[TBL] [Abstract][Full Text] [Related]
14. Increased number of CD25 FoxP3 regulatory T cells in oral squamous cell carcinomas detected by chromogenic immunohistochemical double staining.
Schwarz S; Butz M; Morsczeck C; Reichert TE; Driemel O
J Oral Pathol Med; 2008 Sep; 37(8):485-9. PubMed ID: 18355177
[TBL] [Abstract][Full Text] [Related]
15. [Five year survival of patients with primary oral squamous cell carcinoma. Comparison of two treatment protocols in a prospective study].
Kessler P; Grabenbauer G; Leher A; Bloch-Birkholz A; Vairaktaris E; Neukam FW; Sauer R
Strahlenther Onkol; 2007 Apr; 183(4):184-9. PubMed ID: 17406799
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of cell mediated immunity in advanced pancreatic carcinoma before and after treatment with interleukin-2 (IL-2).
Abdel-Wahab M; El-Shennawy F; Agha S; Ragab E; Fathi O; Sultan A; Elghawalby N; Ezzat F
Hepatogastroenterology; 1999 May; 46 Suppl 1():1293-6. PubMed ID: 10429977
[TBL] [Abstract][Full Text] [Related]
17. Predominant infiltration of macrophages and CD8(+) T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer.
Kawai O; Ishii G; Kubota K; Murata Y; Naito Y; Mizuno T; Aokage K; Saijo N; Nishiwaki Y; Gemma A; Kudoh S; Ochiai A
Cancer; 2008 Sep; 113(6):1387-95. PubMed ID: 18671239
[TBL] [Abstract][Full Text] [Related]
18. Phase II randomized study of interleukin-2 with or without 13-cis retinoic acid as maintenance therapy in patients with advanced cancer responsive to chemotherapy.
Recchia F; Saggio G; Cesta A; Alesse E; Gallo R; Necozione S; Rea S
Anticancer Res; 2005; 25(4):3149-57. PubMed ID: 16080579
[TBL] [Abstract][Full Text] [Related]
19. Intratumoral recombinant human interleukin-12 administration in head and neck squamous cell carcinoma patients modifies locoregional lymph node architecture and induces natural killer cell infiltration in the primary tumor.
van Herpen CM; van der Laak JA; de Vries IJ; van Krieken JH; de Wilde PC; Balvers MG; Adema GJ; De Mulder PH
Clin Cancer Res; 2005 Mar; 11(5):1899-909. PubMed ID: 15756016
[TBL] [Abstract][Full Text] [Related]
20. Lymph node histology in head and neck cancer: impact of immunotherapy with IRX-2.
Meneses A; Verastegui E; Barrera JL; de la Garza J; Hadden JW
Int Immunopharmacol; 2003 Aug; 3(8):1083-91. PubMed ID: 12860165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
